August 30, 2018

Drug for Progressive MS Shows Promise in Clinical Trials

The Latest from Health Central. Forward to a friend | View Online
 
t.png p.png
8975842d-d31a-4ad4-95a9-bcce47223048.jpg
Drug for Progressive MS Shows Promise in Clinical Trials
Health Central — Cleveland Clinic researchers led phase 2 clinical trials for an oral medication, ibudilast, that slowed brain shrinkage in people with progressive multiple sclerosis by 48 percent.
Read More »
STD Rates Hit New Highs for the Fourth Straight Year
CDC — Preliminary information from the CDC suggests nearly 2.3 million cases of chlamydia, gonorrhea, and syphilis were diagnosed in the U.S. in 2017.
Read More »
Many U.S. Soldiers Who Attempt Suicide Have No Mental Illness History
JAMA Psychiatry — Among the 9,650 soldiers in the U.S. Army with a documented suicide attempt, more than a third had no previous mental health diagnosis, according to new data.
Read More »
Antidepressants and Sexual Problems
Berkeley Wellness — People who take antidepressants often experience sex­ual problems, including erectile dysfunction, which can begin immediately or several months after starting treatment for depression.
Read More »
7 Things You Don't Know About Diabetes Unless You Have It
HealthCentral — If living with diabetes were as simple as it's portrayed, the cure would involve an insulin pump, a diet of oatmeal and chicken rather than ice cream and doughnuts, and weight loss. Wrong.
Read More »
imp?s=187247&sz=300x250&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb
imp?s=187248&sz=1x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=187249&sz=1x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb
imp?s=95371&sz=116x15&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=96074&sz=69x15&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb
More from Health Central
The Remedy Health Network
Berkeley Wellness science-backed, expert-vetted health and wellness advice

The Body current and complete coverage for the HIV/AIDS community
Newsletter Options
This email was sent to clrmyers6@gmail.com

We're happy to help you unsubscribe or manage your email preferences.

If this email was forwarded to you by another email recipient and you would like to subscribe, click here.

Ensure you receive this newsletter by adding us to your safe sender's list.

You can also forward this newsletter to a friend.
t.png p.png
imp?s=124359000&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359001&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359002&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359003&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359004&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359005&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359006&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359007&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359008&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359009&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359010&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359011&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359012&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359013&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359014&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359015&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359016&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359017&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359018&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb imp?s=124359019&sz=2x1&li=%7BLIST_ID%7D&e=clrmyers6@gmail.com&p=dff5717cbb

No comments:

Post a Comment